C.M. Bidwell & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-644
Closed -$80K – 474
2025
Q1
$80K Sell
644
-15
-2% -$1.96K 0.05% 175
2024
Q4
$81.2K Sell
659
-3
-0.5% -$354 0.05% 187
2024
Q3
$73.8K Buy
+662
New +$72.5K 0.05% 202
2023
Q4
– Sell
-1,093
Closed -$141K – 534
2023
Q3
$141K Buy
+1,093
New +$146K 0.11% 163
2023
Q2
– Sell
-689
Closed -$101K – 556
2023
Q1
$101K Sell
689
-52
-7% -$7.69K 0.08% 231
2022
Q4
$118K Buy
741
+451
+156% +$66.1K 0.09% 197
2022
Q3
$39K Hold
290
– – 0.03% 290
2022
Q2
$45K Hold
290
– – 0.04% 284
2022
Q1
$45K Buy
+290
New +$42.1K 0.03% 293
2021
Q3
– Sell
-1,615
Closed -$287K – 588
2021
Q2
$287K Buy
1,615
+155
+11% +$26.8K 0.19% 95
2021
Q1
$240K Sell
1,460
-200
-12% -$32.9K 0.18% 100
2020
Q4
$274K Sell
1,660
-70
-4% -$10.4K 0.22% 67
2020
Q3
$247K Buy
+1,730
New +$214K 0.23% 79
2019
Q2
– Sell
-1,815
Closed -$259K – 423
2019
Q1
$259K Buy
+1,815
New +$237K 0.26% 106
2014
Q2
– Sell
-1,415
Closed -$196K – 264
2014
Q1
$196K Sell
1,415
-365
-21% -$54.9K 0.05% 144
2013
Q4
$225K Buy
+1,780
New +$184K 0.06% 149

Other funds holding JAZZ

C.M. Bidwell & Associates's JAZZ Position: Q2 2025 in Review

C.M. Bidwell & Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 644 shares — an estimated $80K sold.

C.M. Bidwell & Associates first reported a position in JAZZ in Q4 2013 and held it in 16 quarters. The position peaked at $287K in Q2 2021. 502 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • C.M. Bidwell & Associates reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 644 Jazz Pharmaceuticals shares in Q2 2025, an estimated $80K.
  • C.M. Bidwell & Associates first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 16 quarters.
  • C.M. Bidwell & Associates's Jazz Pharmaceuticals position peaked at $287K in Q2 2021.
  • 502 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2025, filed 14 Aug 2025.